Virtu KCG Holdings’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Virtu KCG Holdings’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$331K	Buy	+11,002	New	+$343K	0.01%	1560

Other funds holding FPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Virtu KCG Holdings's FPRX Position: Q2 2017 in Review

Virtu KCG Holdings opened a new position in Five Prime Therapeutics, Inc. (FPRX) in Q2 2017: 11,002 shares worth $331K. The stake represents 0.01% of the portfolio and ranks #1560 among its holdings.

123 funds tracked by Wall St. Rank hold FPRX as of Q2 2017.

Virtu KCG Holdings held 11,002 shares of Five Prime Therapeutics, Inc. worth $331K as of Q2 2017.
Five Prime Therapeutics, Inc. was a new Virtu KCG Holdings position in Q2 2017.
Five Prime Therapeutics, Inc. made up 0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #1560 holding.
123 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.